Partnerships & Alliances

Found 54,305 articles

• Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

  5/22/2023

  Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

• Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

  5/22/2023

  Yaral Pharma Inc. today announced its expanding partnership with EVERSANA ® , a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S.

• Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer

  5/22/2023

  Panbela Therapeutics, Inc. today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC).

• Croda and Botanical Solution Inc. (BSI) Announce Partnership to Accelerate Production of Sustainable Vaccine Adjuvant QS-21

  5/22/2023

  Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems.

• Intellego Technologies Partners With HAI Solutions for a Novel Application of Ultraviolet Photochromic Ink for an Intravenous Port Disinfection Technology to Mitigate Risk of Contamination

  5/22/2023

  Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access.

• Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)

  5/22/2023

  Tonix Pharmaceuticals Holding Corp. today announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

• RedHill Provides R&D Update

  5/22/2023

  RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19.

• Avantor® and Labguru Collaborate to Drive More Efficient Lab Buying Experience

  5/22/2023

  Avantor, Inc. has entered into an agreement with Labguru, a research-to-production platform of choice for leading global pharma, national research institutes and innovative startups, to integrate Avantor's Inventory Manager and e-commerce channel into Labguru's Lab Information Management Software (LIMS) and Electronic Lab Notebook (ELN).

• AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

  5/22/2023

  AVROBIO, Inc today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.

• PaceMate Announces First-in-Market Collaboration with AliveCor to Offer the Only Remote Cardiac Remote Monitoring Platform to Encompass Consumer ECG, Event Monitoring, Heart Failure, and Implantable Cardiac Devices

  5/19/2023

  PaceMate ® announced today its collaboration with AliveCor ® , the global leader in FDA-cleared personal electrocardiogram technology and remote patient management solutions for the cardiovascular industry.

• AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

  5/19/2023

  Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

• Plandai Subsidiary ByoPlanet Announces Strategic Distribution Agreement with Merck Animal Health

  5/19/2023

  ByoPlanet is excited to announce the establishment of a comprehensive one-year distribution agreement with Merck Animal Health, a global leader in animal health solutions and a division of Merck & Co.

• Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

  5/19/2023

  Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems.

• 

  AstraZeneca Deepens Gene Editing Capabilities with Revvity Partnership

  5/18/2023

  Under a non-exclusive agreement, AstraZeneca is licensing biotech Revvity’s base editing technology to help create cell therapies for the treatment of cancer and immune-mediated diseases.

• New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

  5/18/2023

  Bausch Health Companies Inc. today announced the publication of a new study, which showed that ARESTIN (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults with periodontitis when applied immediately after scaling and root planning (SRP) and again at a three-month reapplication, versus SRP alone.

• Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

  5/18/2023

  uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-106 and future pipeline.

• DISCOVERY LIFE SCIENCES JOINS AKOYA BIOSCIENCES' GLOBAL SERVICE PROVIDER NETWORK TO ACCELERATE IMMUNO-ONCOLOGY RESEARCH

  5/18/2023

  Discovery Life Sciences ™  (Discovery), the Biospecimen and Biomarker Specialists ™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers.

• Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

  5/18/2023

  Vifor Fresenius Medical Care Renal Pharma today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia ® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

• Newly Presented Preclinical Data Shows Potential for Novel Gene Therapy To Treat Opioid Use Disorder – Second Year of NID/ANIH Grant Support Will Enable Further Exploration of Hypothesis

  5/18/2023

  Copernicus Therapeutics, Inc., today announced preliminary data, in collaboration with Northeastern University and Tufts University, that demonstrated plasmid GDNF DNA nanoparticles (pGDNF NPs) delivered intranasally bypass the blood-brain barrier to allow gene expression in brain cells, which ultimately results in a reduction in drug-seeking behaviors in rats.

• iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes and Receive US $1.0 Million Grant from the BIRD Foundation

  5/18/2023

  iTolerance, Inc. announced that it has entered into a research collaboration agreement with Israeli-based company, Kadimastem, to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression.